OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer

oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]

AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

National study to use genetic testing to guide cancer survivor follow-up / 22 days

Liquid biopsy blood test promises personalized lung cancer detection and monitoring / 4 days

DESTINY‑Lung03: T‑DXd shows activity in HER2 lung cancer; triplet stalls / 33 hrs

Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 20 days

Ultra‑sensitive ctDNA blood test could personalize breast cancer care for older women / 2 months

FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 20 days

High‑dose targeted radiation shows promise for huge bile duct tumors / 1 month